HighTower Advisors LLC Acquires 98,626 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

HighTower Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 408.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 122,770 shares of the company’s stock after buying an additional 98,626 shares during the period. HighTower Advisors LLC’s holdings in Recursion Pharmaceuticals were worth $830,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Victory Capital Management Inc. grew its position in Recursion Pharmaceuticals by 25.1% in the third quarter. Victory Capital Management Inc. now owns 27,394 shares of the company’s stock valued at $181,000 after acquiring an additional 5,503 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter valued at approximately $349,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after purchasing an additional 288,926 shares during the last quarter. Centaurus Financial Inc. acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $71,000. Finally, Qsemble Capital Management LP bought a new position in Recursion Pharmaceuticals in the 3rd quarter valued at approximately $224,000. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $5.97 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36. The firm has a market cap of $2.40 billion, a PE ratio of -3.90 and a beta of 0.85. The firm’s fifty day moving average is $7.46 and its 200-day moving average is $7.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.42) earnings per share. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.